Albany Medical College

Xillus, Inc.

Mark D Scott

John W Eaton

Audra Lynn Stinchcomb

Julian Van Erlach

Arlen L Olsen

Jeffrey M Smith

Gerald E Bender

Roger D Whitmer

Denis P Donnelly

James E Peterson

Gerald F Dudding

Laura B Smith

The present invention is directed to a non-immunogenic cellular composition comprising: a cell having a cell surface and antigenic determinants on the cell surface; an optional linker molecule covalently attached to the cell surface; and a hydrophilic, biocompatible, non-immunogenicity providing compound or polymer (e.g., polyethylene glycol or a derivative thereof) covalently attached to the linker molecule or directly to the cell. In one embodiment, the linker molecule is covalently attached directly to the antigenic determinant on the cell surface. In an alternate embodiment, the linker molecule may be covalently attached to a non-antigenic site on the cell surface, but will camouflage the antigenic determinant on the cell surface. Various uses of the resulting non-immunogenic cell are also provided, including a method of decreasing phagocytosis of a cell, a method of decreasing an adverse reaction to a transfusion, a method of decreasing rejection of a transplanted cell, tissue or organ, and a method of decreasing antibody-induced aggregation of cells.

Antigenic modulation of cells

An in-vivo method and apparatus is disclosed that comprises at least one sensor for determining changes in a human's an animal's body and reporting said changes outside the body. The sensor may be embedded in a sheath. The apparatus may be used to monitor chemical or physical changes in the body fluids. Alternatively, the apparatus may be used to monitor and regulate chemical or physical levels in humans and animals.

Nanodevices, microdevices and sensors on in-vivo structures and method for the same

A chemo-physiological structure and method for forming the chemo-physiological structure. In a first embodiment, a cell of an animal is provided. The cell has a membrane surface and a viral receptor coupled to the membrane surface. A linker molecule having a covalently attached polymer is covalently bonded to the membrane surface, the viral receptor, or both. The polymer prevents an extracellular virus from bonding to the viral receptor. In a second embodiment, a linker molecule having a covalently attached polymer is covalently bonded to a capsid of a virus, which prevents the virus from bonding to a viral receptor of an adjacent or nearby animal cell.

Covalent attachment of polymer to cell to prevent virus bonding to receptor

A prion-physiological structure and associated method of formation. A provided abnormal prion has a transforming power over a normal prion to convert the abnornal prion into defective prion that mimics the abnormal prion. A linker molecule is then bonded to the abnormal prion, wherein a polymer that is covalently attached to the linker molecule facilitates formation of a polymerized abnormal prion that does not have the transforming power over the normal prion.

Covalent modification of abnormal prion protein

A method and structure for forming a viral-physiological structure. A naked virus having a capsid is provided. A linker molecule having a covalently attached polymer is covalently bonded to the capsid to form a polymer-protected virus. An immunogenicity of the polymer-protected virus with respect to an animal exceeds an immunogenicity of the naked virus with respect to the animal.

Enhancement of oligomeric viral immunogenicity

The present invention is directed to a non-immunogenic cellular composition comprising: a cell having a cell surface and antigenic determinants on the cell surface; a linker molecule covalently attached to the cell surface; and a non-immunogenic compound (e.g., polyethylene glycol or derivative thereof) covalently attached to the linker molecule. In one embodiment, the linker molecule is covalently attached directly to the antigenic determinant on the cell surface. In an alternate embodiment, the linker molecule may be covalently attached to a non-antigenic site on the cell surface, but will camouflage the antigenic determinant on the cell surface by virtue of the long chain length of the non-immunogenic compound. Various uses of the resulting non-immunogenic cell are also provided, including a method of decreasing phagocytosis of a cell, a method of decreasing an adverse reaction to a transfusion, a method of decreasing rejection of a transplanted cell, tissue or organ, and a method of decreasing antibody-induced aggregation of cells.

Growing community of inventors

Clifton Park, NY, United States of America

Mark D Scott